SG11202009872YA - Stable antibody formulation - Google Patents

Stable antibody formulation

Info

Publication number
SG11202009872YA
SG11202009872YA SG11202009872YA SG11202009872YA SG11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA
Authority
SG
Singapore
Prior art keywords
antibody formulation
stable antibody
stable
formulation
antibody
Prior art date
Application number
SG11202009872YA
Other languages
English (en)
Inventor
Murali Jayaraman
Anuja Chandrasekar
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68164052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202009872Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of SG11202009872YA publication Critical patent/SG11202009872YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202009872YA 2018-04-10 2019-04-10 Stable antibody formulation SG11202009872YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841013645 2018-04-10
PCT/IN2019/050291 WO2019198099A1 (en) 2018-04-10 2019-04-10 Stable antibody formulation

Publications (1)

Publication Number Publication Date
SG11202009872YA true SG11202009872YA (en) 2020-11-27

Family

ID=68164052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009872YA SG11202009872YA (en) 2018-04-10 2019-04-10 Stable antibody formulation

Country Status (10)

Country Link
US (1) US12024561B2 (enExample)
EP (1) EP3773695A4 (enExample)
JP (1) JP2021521168A (enExample)
CN (1) CN112243379A (enExample)
AU (1) AU2019251452A1 (enExample)
BR (1) BR112020020741A2 (enExample)
CO (1) CO2020013545A2 (enExample)
SG (1) SG11202009872YA (enExample)
WO (1) WO2019198099A1 (enExample)
ZA (1) ZA202006262B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2236154T3 (en) * 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
US12433947B2 (en) * 2018-04-10 2025-10-07 Dr. Reddy's Laboratories Limited Stable formulations of therapeutic antibody
WO2019198100A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Antibody formulation
CN114375307B (zh) * 2019-06-10 2025-12-05 武田药品工业株式会社 产生抗α4β7抗体的方法
EP3980119A4 (en) * 2019-06-10 2023-06-07 Takeda Pharmaceutical Company Limited METHODS FOR PURIFYING ANTIBODIES AND ASSOCIATED COMPOSITIONS

Also Published As

Publication number Publication date
WO2019198099A1 (en) 2019-10-17
US20210253714A1 (en) 2021-08-19
CN112243379A (zh) 2021-01-19
EP3773695A4 (en) 2021-12-22
EP3773695A1 (en) 2021-02-17
US12024561B2 (en) 2024-07-02
CO2020013545A2 (es) 2021-01-18
AU2019251452A1 (en) 2020-11-26
BR112020020741A2 (pt) 2021-01-19
JP2021521168A (ja) 2021-08-26
AU2019251452A2 (en) 2020-12-03
ZA202006262B (en) 2023-01-25

Similar Documents

Publication Publication Date Title
IL269499A (en) Stable antibody formulation
ZA202006263B (en) Antibody formulation
SG11202103064YA (en) Antibody formulation
IL282617A (en) Aerosol formulation
IL281255A (en) CSF-1R antibody formulation
SG11202104300PA (en) Antibody formulation
IL282567A (en) Aerosol formulation
IL282523A (en) Aerosol formulation
IL282589A (en) Aerosol formulation
GB201816447D0 (en) Formulation
SG11202102875YA (en) Anti-fgfr2 antibody formulations
GB201801614D0 (en) Formulation
IL282461A (en) Aerosol formulation
SG11202104012QA (en) Antibody formulations
IL282697A (en) Aerosol formulation
GB201817863D0 (en) Aerosolisable formulation
ZA202006262B (en) Stable antibody formulation
GB201813229D0 (en) Formulation
GB201811926D0 (en) Aerosolisable formulation
GB201807312D0 (en) Formulation
HK40061150A (en) Antibody formulation
HK40048229A (en) Antibody formulation
HK40025055A (en) Stable anti-osmr antibody formulation
GB201817866D0 (en) Aerosolisable formulation
GB201809575D0 (en) Formulation